Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Zydus Cadila total...

    Zydus Cadila total income up by 21 percent to Rs 3496 crore in Q1

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-10T12:43:01+05:30  |  Updated On 13 Aug 2021 4:22 PM IST

    During the quarter, Zydus Cadila entered into a marketing alliance with SIFI, the Italian leader in the development of therapeutic solutions for treating ophthalmic disorders, to market innovative intraocular lenses and surgical products developed in Italy and licensed in India by SIFI.


    Ahmedabad: Pharmaceuticals major Zydus Cadila on Friday reported total income from operations of Rs 3,496 crore in the first quarter ended June 30, up by 21 per cent on a year-on-year basis.


    Earnings before interest, depreciation and tax (EBIDTA) for the quarter were Rs 632 crore while the net profit stood at Rs 304 crore.


    The company's India business which comprises human formulations, consumer wellness and animal health business posted sales of Rs 1,675 crore, up by 46 per cent.


    During the quarter, the company entered into a marketing alliance with SIFI, the Italian leader in the development of therapeutic solutions for treating ophthalmic disorders, to market innovative intraocular lenses and surgical products developed in Italy and licensed in India by SIFI.


    Read Also: CDSCO approves Zydus, SIFI pact to launch Intraocular Lenses in India


    The company's business in the United States posted sales of Rs 1,367 crore, up by 11 per cent. During the quarter, the company launched eight new products. Its business in emerging markets of Asia, Africa, and Latin America grew by 12 percent and posted sales of Rs 220 crore.


    Read Also: Zydus Cadila wins USFDA nod for Minocycline Hydrochloride ER tablets to treat acne

    market allianceophthalmic disorderpharmapharma newspharma news indiaSIFItherapeutical productszydusZydus CadilaZydus cadila incomeZydus Cadila June quarterZydus cadila profitZydus collaborationZydus Q1Zydus surgical product
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok